Abstract

We present the case of a girl with CRIA syndrome treated with sirolimus with significant reduction in the number of days with fever, the total dose of glucocorticoids used and the inflammatory markers levels, together with a reduction in the double negative T-cells and control of PI3K/mTor Activity. We propose sirolimus as a valid therapeutic choice in patients with CRIA syndrome.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.